Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia



Status:Completed
Conditions:Bronchitis, Women's Studies, Hematology
Therapuetic Areas:Hematology, Pulmonary / Respiratory Diseases, Reproductive
Healthy:No
Age Range:Any
Updated:8/20/2016
Start Date:May 2012
End Date:August 2016

Use our guide to learn which trials are right for you!

The purpose of this study is to identify biological markers that might predict premature
infants who are at a higher risk for developing BPD, and to correlate the presence of these
markers with infant symptoms and lung function in the first year after discharge from the
hospital.

Bronchopulmonary dysplasia (BPD) is a common form of lung injury that can be triggered by
premature birth and the unavoidable exposures to treatments regularly used for premature
infants,including mechanical ventilation and oxygen as well as conditions that occur
frequently among premature infants including infection. Almost all infants who are born
prematurely are exposed to either mechanical ventilation, extra oxygen, and many will
develop at least one infection; however, not all premature infants will develop BPD. There
is currently no way to identify those infants who are at risk for developing BPD, nor are
there prognostic or diagnostic tests to determine the severity of lung disease in the first
year after discharge from the hospital.

The application of UPLC-tandem mass spectrometry for quantification of urinary biomarkers of
oxidative stress is an important technical innovation that will permit sensitive and
reproducible analyses of urinary biomarkers with minimal sample preparation to better define
disease phenotypes. Establishing a direct correlation between biomarkers of oxidative stress
and GRP will accelerate investigation into the mechanisms leading to chronic pediatric lung
disease and childhood origins of pulmonary disease.

Inclusion Criteria:

- Gestational age at birth 23-0/7 to 27-6/7 weeks post-menstrual age

Exclusion Criteria:

- Are not considered to be viable (decision made not to provide life-saving therapies)

- Have congenital heart disease (not including PDA and hemodynamically insignificant
VSD or ASD)

- Have structural abnormalities of the upper airway, lungs or chest wall

- Have other congenital malformations or syndromes that adversely affect life
expectancy or cardio-pulmonary development

- Unlikely to return to the clinic for follow-up visits
We found this trial at
2
sites
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials